T Cell Receptor cDNAs to Treat Gliomas

Technology Description

Mutations in the isocitrate dehydrogenase (IDH) metabolic enzymes IDH1 and IDH2 are frequently found in gliomas. Mutations in an HLA-class II binding CD4 T-cell epitope of IDH1, termed IDH1R132H, are present in 70-80% of WHO grade II and III glioma patients. In collaboration with Berlkeley Lights Inc., scientists at UCSF have recently cloned cDNAs that code for T-cell receptors that react with a peptide derived from isocitrate dehydrogenase 1 mutated at residue 132 (IDH1R132H). Immunizing mice bearing IDH1R132H-transfected syngeneic sarcomas with the IDH1R132H peptide was shown to have an anti-tumor effect. The cDNAs developed can, therefore, be used to develop adoptive T-cell therapies for cancers bearing the IDH1R132H mutation.

ADVANTAGES

• The new T cell receptors can recognize IDH proteins that are mutated in most gliomas
• Can improve the design of safe and effective cancer immunotherapy
• Cancer immunotherapy targeting IDH1R132H has the potential to be more effective than vaccination

Patent Status